Cost-effectiveness analysis of ivonescimab plus chemotherapy in advanced squamous NSCLC: a Chinese healthcare system perspective with U.S. pricing scenario exploration
4 affiliations
- 1The First Affiliated Hospital of Xiamen University
- 2Department of Pharmacy, Zhongshan Hospital Fudan University Xiamen Branch
- 3Clinical Research Center for Cancer Therapy, Zhongshan Hospital Fudan University
- 4Xiamen Professional Quality Control Center for Comprehensive Pharmaceutical Affairs Management
Abstract
Background: Ivonescimab plus chemotherapy shows outstanding efficacy for advanced squamous non-small cell lung cancer (NSCLC), but its pharmacoeconomic value remains to be determined. Therefore, this study seeks to evaluate the cost-effectiveness of the ivonescimab regimen for advanced squamous NSCLC from the Chinese and U.S. healthcare perspectives, and to explore the theoretical cost-effective price threshold of ivonescimab.
Methods: Survival curves from the HARMONi-6 trial were fitted and extrapolated, and direct medical costs were calculated. A partitioned survival model was developed within TreeAge Pro to project disease trajectory and resource utilization over a 10-year time horizon. The primary outcome was the incremental cost-effectiveness ratio (ICER), compared against willingness-to-pay (WTP) to assess the ivonescimab regimen’s cost-effectiveness. Sensitivity, scenario, and threshold analyses were performed to assess parameter uncertainty and estimate ivonescimab’s theoretical cost-effective price threshold.
Results: In China, the ivonescimab group cost $60,942 for 2.33 QALYs versus $30,093 for 1.57 QALYs in the tislelizumab group, yielding an ICER of $40,328/QALY. Utility during progressive disease was the most influential parameter. Ivonescimab’s theoretical cost-effective price thresholds were $27.85/100mg, $67.63/100mg, and $107.4/100mg, corresponding to WTPs of single, double, and triple the per-capita GDP, respectively. In the U.S., the total costs were $572,981 and $419,922, and the health outcomes were 3.16 QALYs and 2.19 QALYs for the two arms, with an ICER of $157,444/QALY. Ivonescimab’s price was the dominant driver of ICER. The theoretical cost-effective price thresholds were $609.10/100 mg and $777.31/100mg, corresponding to the $100,000/QALY and $150,000/QALY WTP, respectively.
Conclusion: Under the unified model framework of this study, compared with the tislelizumab regimen, the ivonescimab regimen as the first-line treatment for advanced squamous NSCLC in both countries is unlikely to have a cost-effectiveness advantage.
Related
- Cost-effectiveness of disitamab vedotin plus toripalimab versus chemotherapy alone as first-line treatment for HER2-overexpressing advanced urothelial carcinoma: a cost-effectiveness analysis from the Chinese healthcare system perspective
- Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
- Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system.
- Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis
- Healthcare resource utilisation and costs of chemotherapy and autologous haemopoietic cell transplantation of patients with multiple myeloma in China: a multi-centre retrospective analysis
BibTeX
@article{zheng2026costeffectiveness,
title = {{Cost-effectiveness analysis of ivonescimab plus chemotherapy in advanced squamous NSCLC: a Chinese healthcare system perspective with U.S. pricing scenario exploration}},
author = {Linxiong Zheng and Kailong Zhong and Fang Chen and Jiayong Yang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1942976},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1942976/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cost-effectiveness analysis of ivonescimab plus chemotherapy in advanced squamous NSCLC: a Chinese healthcare system perspective with U.S. pricing scenario exploration
AU - Linxiong Zheng
AU - Kailong Zhong
AU - Fang Chen
AU - Jiayong Yang
PY - 2026
DA - 2026/10/27
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1942976
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1942976/full
AB - Background: Ivonescimab plus chemotherapy shows outstanding efficacy for advanced squamous non-small cell lung cancer (NSCLC), but its pharmacoeconomic value remains to be determined. Therefore, this study seeks to evaluate the cost-effectiveness of the ivonescimab regimen for advanced squamous NSCLC from the Chinese and U.S. healthcare perspectives, and to explore the theoretical cost-effective price threshold of ivonescimab. Methods: Survival curves from the HARMONi-6 trial were fitted and extrapolated, and direct medical costs were calculated. A partitioned survival model was developed within TreeAge Pro to project disease trajectory and resource utilization over a 10-year time horizon. The primary outcome was the incremental cost-effectiveness ratio (ICER), compared against willingness-to-pay (WTP) to assess the ivonescimab regimen’s cost-effectiveness. Sensitivity, scenario, and threshold analyses were performed to assess parameter uncertainty and estimate ivonescimab’s theoretical cost-effective price threshold. Results: In China, the ivonescimab group cost $60,942 for 2.33 QALYs versus $30,093 for 1.57 QALYs in the tislelizumab group, yielding an ICER of $40,328/QALY. Utility during progressive disease was the most influential parameter. Ivonescimab’s theoretical cost-effective price thresholds were $27.85/100mg, $67.63/100mg, and $107.4/100mg, corresponding to WTPs of single, double, and triple the per-capita GDP, respectively. In the U.S., the total costs were $572,981 and $419,922, and the health outcomes were 3.16 QALYs and 2.19 QALYs for the two arms, with an ICER of $157,444/QALY. Ivonescimab’s price was the dominant driver of ICER. The theoretical cost-effective price thresholds were $609.10/100 mg and $777.31/100mg, corresponding to the $100,000/QALY and $150,000/QALY WTP, respectively. Conclusion: Under the unified model framework of this study, compared with the tislelizumab regimen, the ivonescimab regimen as the first-line treatment for advanced squamous NSCLC in both countries is unlikely to have a cost-effectiveness advantage.
SN - 1663-9812
ER -